Sugi Predict

Sugi Predict / Compounds / SCHEMBL4453848

SCHEMBL4453848

SCHEMBL4453848

COc1ccc(Sc2oc3ccc(Cl)cc3c2C)nn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCL1 Q07820 1/20 0.40
▸ AHR P35869 1/20 0.37
▸ AKR1B1 P15121 1/20 0.37
▸ KCNH2 Q12809 2/20 0.36
▸ GABRP O00591 1/20 0.36
▸ GABRD O14764 1/20 0.36
▸ GABRA1 P14867 1/20 0.36
▸ GABRB1 P18505 1/20 0.36
▸ GABRG2 P18507 1/20 0.36
▸ KCNA5 P22460 1/20 0.36
▸ GABRB3 P28472 1/20 0.36
▸ GABRA5 P31644 1/20 0.36
▸ GABRA3 P34903 1/20 0.36
▸ GABRA2 P47869 1/20 0.36
▸ GABRB2 P47870 1/20 0.36
▸ GABRA4 P48169 1/20 0.36
▸ GABRE P78334 1/20 0.36
▸ GABRA6 Q16445 1/20 0.36
▸ GABRG1 Q8N1C3 1/20 0.36
▸ GABRG3 Q99928 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6167578 0.86 MCL1 (0.43) MCL1AHRAKR1B1KCNH2ALDH1A1
SCHEMBL5263709 0.84 AKR1B1 (0.40) AHRAKR1B1KCNH2GABRPGABRD
SCHEMBL6176631 0.84 MCL1 (0.44) MCL1AHRAKR1B1KCNH2ALDH1A1
SCHEMBL4449406 0.79 MCL1 (0.41) MCL1AHRAKR1B1KCNH2ALDH1A1
SCHEMBL4462839 0.74 AKR1B1 (0.60) MCL1AKR1B1KCNH2ALDH1A1ADORA3
SCHEMBL4451859 0.73 AKR1B1 (0.61) MCL1AHRAKR1B1KCNH2GABRP
SCHEMBL4448936 0.71 MCL1 (0.39) MCL1AHRAKR1B1KCNH2GABRP
SCHEMBL6205763 0.70 EGFR (0.45) ALDH1A1KDM4EHPGDLMNAMAPT
SCHEMBL14409919 0.65 MCL1 (0.59) MCL1AHRAKR1B1KCNH2ALDH1A1
SCHEMBL4458218 0.64 AKR1B1 (0.64) AHRAKR1B1KCNH2GABRPGABRD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572910-B2 Pyridazinone aldose reductase inhibitors PFIZER, INC. (US) 2009-08-11 — — US claimed
EP-1491540-B1 Intermediates useful for the synthesis of pyridazinone aldose reductase inhibitors PFIZER PROD INC (US) 2006-12-13 — — EP claimed
US-20050113381-A1 Pyridazinone aldose reductase inhibitors MYLARI BANAVARA L (US) 2005-05-26 — — US claimed
EP-1373259-B1 PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS PFIZER PROD INC (US) 2004-12-29 — — EP claimed
EP-1373259-A1 PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS Pfizer Products Inc. (US) 2004-01-02 — — EP claimed
US-20030162784-A1 Pyridazinone aldose reductase inhibitors MYLARI BANAVARA L (US) 2003-08-28 — — US claimed
WO-2002079198-A1 PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS PFIZER PRODUCTS INC. (US) 2002-10-10 — — WO claimed
US-20020143017-A1 Pyridazinone aldose reductase inhibitors MYLARI BANAVARA L (US) 2002-10-03 — — US claimed
US-7572910-B2 Pyridazinone aldose reductase inhibitors PFIZER, INC. (US) 2009-08-11 — — US disclosed
EP-1491540-B1 Intermediates useful for the synthesis of pyridazinone aldose reductase inhibitors PFIZER PROD INC (US) 2006-12-13 — — EP disclosed
EP-1463725-B1 PROCESS AND INTERMEDIATES FOR PYRIDAZINONE ANTIDIABETIC AGENTS PFIZER PROD INC (US) 2005-08-17 — — EP disclosed
US-20050113381-A1 Pyridazinone aldose reductase inhibitors MYLARI BANAVARA L (US) 2005-05-26 — — US disclosed
US-6849629-B2 Heteroaromatic substituted sulfonyl or sulfoxide or thio-pyridazinone derivatives, useful for treating diabetic complications and cardiovascular disorders PFIZER, INC. (US) 2005-02-01 — — US disclosed
US-20050004124-A1 THERAPIES RELATING TO COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS MYLARI BANAVARA L (US) 2005-01-06 — — US disclosed
US-20030162784-A1 Pyridazinone aldose reductase inhibitors MYLARI BANAVARA L (US) 2003-08-28 — — US disclosed
US-20030162969-A1 Process and intermediates for pyridazinone antidiabetic agents TOM NORMA J (US) 2003-08-28 — — US disclosed
WO-2003057691-A1 PROCESS AND INTERMEDIATES FOR PYRIDAZINONE ANTIDIABETIC AGENTS PFIZER PRODUCTS INC. (US) 2003-07-17 — — WO disclosed
US-6579879-B2 Pyridazinone aldose reductase inhibitors PFIZER INC 2003-06-17 — — US disclosed
WO-2002087584-A1 COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS PFIZER PRODUCTS INC. (US) 2002-11-07 — — WO disclosed
US-20020143017-A1 Pyridazinone aldose reductase inhibitors MYLARI BANAVARA L (US) 2002-10-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113381-A1 Pyridazinone aldose reductase inhibitors SLC5A1, ALDOA, AKR1B1 MCL1 4625/4885AHR 3095/4885AKR1B1 3/4885
US-20030162784-A1 Pyridazinone aldose reductase inhibitors SLC5A1, ALDOA, AKR1B1 MCL1 4625/4885AHR 3095/4885AKR1B1 3/4885
US-20020143017-A1 Pyridazinone aldose reductase inhibitors SLC5A1, AKR1B1, AKR1D1 MCL1 4705/4885AHR 2958/4885AKR1B1 2/4885
US-20050004124-A1 THERAPIES RELATING TO COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS ALDOA, AKR1B1, ALDH2 MCL1 3910/4885AHR 2083/4885AKR1B1 2/4885
US-20030162969-A1 Process and intermediates for pyridazinone antidiabetic agents ALDOA, AKR1B1, DPYD MCL1 4399/4885AHR 2569/4885AKR1B1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.